Quantcast

Latest Denosumab Stories

2008-07-14 09:01:11

Amgen (NASDAQ:AMGN) today announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time...

2006-12-05 12:00:16

Research and Markets (http://www.researchandmarkets.com/reports/c46468) has announced the addition of Espicom Business Intelligence's new report: New Drug Futures: Musculoskeletal Chapter to their offering. Please note this chapter is taken from the "New Drug Futures" report. This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the musculoskeletal...

2006-07-18 18:45:00

Astronauts who travel in space are at risk for bone loss in much the same way that cancer patients who receive radiation therapy are, and both groups are more likely to develop fractures than the general population. To better understand the causes, Clemson researchers have developed the first model to study the rate of bone loss in those two groups. Their results are published in the Journal of Applied Physiology. Clemson bioengineering professor Ted Bateman said, Recent exams of astronauts...

2006-06-04 08:05:00

By Deena Beasley LOS ANGELES (Reuters) - Amgen Inc. said on Sunday that early results from mid-stage trials of its experimental drug denosumab show that it works at least as well as current therapies to limit bone loss in patients with late-stage cancer. A study investigator said that the product, seen as one of Amgen's most promising, was not able to show at this point in time that it is more effective than existing drugs, called bisphosphonates. "There are hints that this drug is...

2006-02-22 17:10:00

By Gene Emery BOSTON (Reuters) - People treated with Amgen Inc.'s experimental drug denosumab twice a year can strengthen the density of bones in the spine, a study said. The formal results of the first year of the test, published in Thursday's New England Journal of Medicine, come three months after Amgen reported on the effects of the drugs after two years of use as part of the same study. The 412 volunteers, who were all women with low bone density, were given the drug -- at one of seven...

2005-11-15 16:13:18

THOUSAND OAKS, Calif. (November 13, 2005) "“ Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced that twice-yearly subcutaneous injections of denosumab (60 mg), (previously referred to as AMG 162), increased bone mineral density (BMD) in the lumbar spine, total hip, distal 1/3 radius and total body compared to placebo at 24 months. The study also included an open label Fosamax®* (alendronate) arm. Investigators reported on a pre-planned...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related